Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis

References

• Liu C, Workman CJ, Vignali DA. Targeting regulatory T cells in tumors. FEBS J. 2016;238:2731–48.
   Google Scholar
• Whiteside TL. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert opinion on biological therapy. 2014;14:1411–25.
   PubMed Web of Science ®Google Scholar
• Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol. 2013;4:190.
   PubMed Web of Science ®Google Scholar
• Burocchi A, Colombo MP, Piconese S. Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol. 2013;4:247.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi:10.1038/nrc3245. PMID:22419253
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–6. doi:10.1038/74704. PMID:10742152
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210:1685–93. doi:10.1084/jem.20130573. PMID:23897982
   PubMed Web of Science ®Google Scholar
• Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med. 2005;202:885–91. doi:10.1084/jem.20050940. PMID:16186187
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695–710. doi:10.1084/jem.20130579. PMID:23897981
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol. 2014;92:475–80. doi:10.1038/icb.2014.26. PMID:24732076
   PubMed Web of Science ®Google Scholar
• Petrillo MG, Ronchetti S, Ricci E, Alunno A, Gerli R, Nocentini G, Riccardi C. GITR+ regulatory T cells in the treatment of autoimmune diseases. Autoimmun Rev. 2015;14:117–26. doi:10.1016/j.autrev.2014.10.011. PMID:25449679
   PubMed Web of Science ®Google Scholar
• Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology. 2001;103:449–57. doi:10.1046/j.1365-2567.2001.01279.x. PMID:11529935
   PubMed Web of Science ®Google Scholar
• Morikawa H, Sakaguchi S. Genetic and epigenetic basis of Treg cell development and function: from a FoxP3-centered view to an epigenome-defined view of natural Treg cells. Immunol Rev. 2014;259:192–205. doi:10.1111/imr.12174. PMID:24712467
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875–86. doi:10.1084/jem.20030152. PMID:14676299
   PubMed Web of Science ®Google Scholar
• Bianchini R, Bistoni O, Alunno A, Petrillo MG, Ronchetti S, Sportoletti P, Bocci EB, Nocentini G, Gerli R, Riccardi C. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. Eur J Immunol. 2011;41:2269–78. doi:10.1002/eji.201040943. PMID:21557210
   PubMed Web of Science ®Google Scholar
• Nocentini G, Cari L, Migliorati G, Riccardi C. The role of GITR single-positive cells in immune homeostasis. Immun Inflamm Dis. 2017;5:4–6. doi:10.1002/iid3.148. PMID:28250919
   PubMed Web of Science ®Google Scholar
• Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, Guo B, Herbert DR, Bulfone A, Trentini F, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013;19:739–46. doi:10.1038/nm.3179. PMID:23624599
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S, Bacchetta R, Battaglia M. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. Curr Top Microbiol Immunol. 2014;380:39–68. PMID:25004813
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011;11:119–30. doi:10.1038/nri2916. PMID:21267013
   PubMed Web of Science ®Google Scholar
• Rezende RM, da Cunha AP, Kuhn C, Rubino S, M'Hamdi H, Gabriely G, Vandeventer T, Liu S, Cialic R, Pinheiro-Rosa N, et al. Identification and characterization of latency-associated peptide-expressing gammadelta T cells. Nat Commun. 2015;6:8726. doi:10.1038/ncomms9726. PMID:26644347
   PubMed Web of Science ®Google Scholar
• Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev. 2014;259:88–102. doi:10.1111/imr.12160. PMID:24712461
   PubMed Web of Science ®Google Scholar
• Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol. 2009;10:689–95. doi:10.1038/ni.1760. PMID:19536194
   PubMed Web of Science ®Google Scholar
• Padovani CT, Bonin CM, Tozetti IA, Ferreira AM, Fernandes CE, Costa IP. Glucocorticoid-induced tumor necrosis factor receptor expression in patients with cervical human papillomavirus infection. Rev Soc Bras Med Trop. 2013;46:288–92. doi:10.1590/0037-8682-0029-2013. PMID:23856878
   PubMed Web of Science ®Google Scholar
• Sacchetti C, Rapini N, Magrini A, Cirelli E, Bellucci S, Mattei M, Rosato N, Bottini N, Bottini M. In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes. Bioconjug Chem. 2013;24:852–8. doi:10.1021/bc400070q. PMID:23682992
   PubMed Web of Science ®Google Scholar
• Ronchetti S, Ricci E, Petrillo MG, Cari L, Migliorati G, Nocentini G, Riccardi C. Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells. J Immunol Res. 2015;2015:171520. doi:10.1155/2015/171520. PMID:25961057
   PubMed Web of Science ®Google Scholar
• Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, Baum D, Defusco A, Plager S, Warden S, Huang D, et al. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal. 2017;10. doi:10.1126/scisignal.aaf8608. PMID:28096513
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of IgG2 a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1:32–42. doi:10.1158/2326-6066.CIR-13-0013. PMID:24777248
   PubMed Web of Science ®Google Scholar
• Gabriely G, da Cunha AP, Rezende RM, Kenyon B, Madi A, Vandeventer T, Skillin N, Rubino S, Garo L, Mazzola MA, et al. Targeting latency-associated peptide promotes antitumor immunity. Science Immunology. 2017;2. doi:10.1126/sciimmunol.aaj1738. PMID:28763794
   PubMed Web of Science ®Google Scholar
• De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, Politano C, Bonnal RJ, Provasi E, Sarnicola ML, Panzeri I, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity. 2016;45:1135–47. doi:10.1016/j.immuni.2016.10.021. PMID:27851914
   PubMed Web of Science ®Google Scholar
• Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, Chudakov DM, Rudensky AY. Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. Immunity. 2016;45:1122–34. doi:10.1016/j.immuni.2016.10.032. PMID:27851913
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–95. doi:10.1016/j.immuni.2013.10.003. PMID:24138885
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48–61. doi:10.1016/j.cell.2014.12.033. PMID:25594174
   PubMed Web of Science ®Google Scholar
• Şenbabaoğlu Y, Winer AG, Gejman RS, Liu M, Luna A, Ostrovnaya I, Weinhold N, Lee W, Kaffenberger SD, Chen YB, et al. The landscape of T cell infiltration in human cancer and its association with antigen presenting gene expression. bioRxiv. 2015.
   Google Scholar
• Hruz T, Laule O, Szabo G, Wessendorp F, Bleuler S, Oertle L, Widmayer P, Gruissem W, Zimmermann P. Genevestigator v3: a reference expression database for the meta-analysis of transcriptomes. Adv Bioinformatics. 2008;2008:420747. doi:10.1155/2008/420747. PMID:19956698
   PubMedGoogle Scholar
• Mandal R, Senbabaoglu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1:e89829. doi:10.1172/jci.insight.89829. PMID:27777979
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248–62. doi:10.1016/j.celrep.2016.12.019. PMID:28052254
   PubMed Web of Science ®Google Scholar
• Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux P, Rudnev D, Lash AE, Fujibuchi W, Edgar R. NCBI GEO: mining millions of expression profiles-database and tools. Nucleic Acids Res. 2005;33:D562–6. doi:10.1093/nar/gki022. PMID:15608262
   PubMed Web of Science ®Google Scholar
• Kolesnikov N, Hastings E, Keays M, Melnichuk O, Tang YA, Williams E, Dylag M, Kurbatova N, Brandizi M, Burdett T, et al. ArrayExpress update-simplifying data submissions. Nucleic Acids Res. 2015;43:D1113–6. doi:10.1093/nar/gku1057. PMID:25361974
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautes-Fridman C, Fridman WH, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218. doi:10.1186/s13059-016-1070-5. PMID:27765066
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–71. doi:10.1146/annurev-immunol-031210-101324. PMID:21219185
   PubMed Web of Science ®Google Scholar
• Diederichsen AC, Hjelmborg J, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother. 2003;52:423–8. doi:10.1007/s00262-003-0388-5. PMID:12695859
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest. 2007;117:1167–74. doi:10.1172/JCI31202. PMID:17476346
   PubMed Web of Science ®Google Scholar
• Clancy T, Hovig E. Profiling networks of distinct immune-cells in tumors. BMC Bioinformatics. 2016;17:263. doi:10.1186/s12859-016-1141-3. PMID:27377892
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766–72. PMID:11406550
   PubMed Web of Science ®Google Scholar
• Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756–61. doi:10.4049/jimmunol.169.5.2756. PMID:12193750
   PubMed Web of Science ®Google Scholar
• Massague J. TGFbeta in Cancer. Cell. 2008;134:215–30. doi:10.1016/j.cell.2008.07.001. PMID:18662538
   PubMed Web of Science ®Google Scholar
• Alshaker HA, Matalka KZ. IFN-gamma, IL-17 and TGF-beta involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int. 2011;11:33. doi:10.1186/1475-2867-11-33. PMID:21943203
   PubMed Web of Science ®Google Scholar
• Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol. 1997;159:664–73. PMID:9218581
   PubMed Web of Science ®Google Scholar
• Wu C, Thalhamer T, Franca RF, Xiao S, Wang C, Hotta C, Zhu C, Hirashima M, Anderson AC, Kuchroo VK. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity. 2014;41:270–82. doi:10.1016/j.immuni.2014.06.011. PMID:25065622
   PubMed Web of Science ®Google Scholar
• Rifkin DB. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem. 2005;280:7409–12. doi:10.1074/jbc.R400029200. PMID:15611103
   PubMed Web of Science ®Google Scholar
• Bu M, Shen Y, Seeger WL, An S, Qi R, Sanderson JA, Cai Y. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression. Tumour Biol. 2016;37:3949–56. doi:10.1007/s13277-015-4237-x. PMID:26482613
   PubMedGoogle Scholar
• Madireddi S, Eun SY, Lee SW, Nemcovicova I, Mehta AK, Zajonc DM, Nishi N, Niki T, Hirashima M, Croft M. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J Exp Med. 2014;211:1433–48. doi:10.1084/jem.20132687. PMID:24958847
   PubMed Web of Science ®Google Scholar
• Kang CW, Dutta A, Chang LY, Mahalingam J, Lin YC, Chiang JM, Hsu CY, Huang CT, Su WT, Chu YY, et al. Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. Sci Rep. 2015;5:15659. doi:10.1038/srep15659. PMID:26493689
   PubMed Web of Science ®Google Scholar
• Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A. 2009;106:13445–50. doi:10.1073/pnas.0901944106. PMID:19651619
   PubMed Web of Science ®Google Scholar
• Knee DA, Hewes B, Brogdon JL. Rationale for anti-GITR cancer immunotherapy. Eur J Cancer. 2016;67:1–10. doi:10.1016/j.ejca.2016.06.028. PMID:27591414
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013;123:2447–63. doi:10.1172/JCI64859. PMID:23728179
   PubMed Web of Science ®Google Scholar
• Nocentini G, Cari L, Ronchetti S, Riccardi C. Modulation of tumor immunity: a patent evaluation of WO2015026684A1. Expert Opin Ther Pat. 2016;26:417–25. doi:10.1517/13543776.2016.1118061. PMID:26560753
   PubMed Web of Science ®Google Scholar
• Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One. 2010;5:e10436. doi:10.1371/journal.pone.0010436. PMID:20454651
   PubMed Web of Science ®Google Scholar
• Nocentini G, Cari L, Riccardi C. GITR: A Modulator of Regulatory and Effector T-cell Activity, Crucial in Tumour Rejection and Autoimmune Diseses. eLS. Chichester: John Wiley & Sons Ltd, 2017. doi:10.1002/9780470015902.a0026242.
   Google Scholar
• Kim YH, Shin SM, Choi BK, Oh HS, Kim CH, Lee SJ, Kim KH, Lee DG, Park SH, Kwon BS. Authentic GITR signaling fails to induce tumor regression unless Foxp3+ Regulatory T cells are depleted. J Immunol. 2015;195:4721–9. doi:10.4049/jimmunol.1403076. PMID:26423152
   PubMed Web of Science ®Google Scholar
• Miska J, Rashidi A, Chang AL, Muroski ME, Han Y, Zhang L, Lesniak MS. Anti-GITR therapy promotes immunity against malignant glioma in a murine model. Cancer Immunol Immunother. 2016;65:1555–67. doi:10.1007/s00262-016-1912-8. PMID:27734112
   PubMed Web of Science ®Google Scholar
• Leyland R, Watkins A, Mulgrew K, Holoweckyj N, Bamber L, Tigue NJ, Offer E, Andrews J, Yan L, Mullins S, et al. A novel murine GITR ligand fusion protein induces antitumor activity as a monotherapy, which is further enhanced in combination with an OX40 agonist. Clin Cancer Res. 2017;23(13):3416–3427. doi:10.1158/1078-0432.CCR-16-2000. PMID:28069723
   PubMed Web of Science ®Google Scholar
• Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, Sharpe AH, Kuchroo VK. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186:1338–42. doi:10.4049/jimmunol.1003081. PMID:21199897
   PubMed Web of Science ®Google Scholar
• Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40:569–81. doi:10.1016/j.immuni.2014.02.012. PMID:24745333
   PubMed Web of Science ®Google Scholar
• Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW, Smyth MJ, Kuchroo VK, Anderson AC. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125:4053–62. doi:10.1172/JCI81187. PMID:26413872
   PubMed Web of Science ®Google Scholar
• Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, et al. Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226. J Immunol. 2015;195:145–55. doi:10.4049/jimmunol.1402381. PMID:25994968
   PubMed Web of Science ®Google Scholar
• Chen ML, Yan BS, Bando Y, Kuchroo VK, Weiner HL. Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol. 2008;180:7327–37. doi:10.4049/jimmunol.180.11.7327. PMID:18490732
   PubMed Web of Science ®Google Scholar
• Scurr M, Ladell K, Besneux M, Christian A, Hockey T, Smart K, Bridgeman H, Hargest R, Phillips S, Davies M, et al. Highly prevalent colorectal cancer-infiltrating LAP(+) Foxp3(-) T cells exhibit more potent immunosuppressive activity than Foxp3(+) regulatory T cells. Mucosal Immunol. 2014;7:428–39. doi:10.1038/mi.2013.62. PMID:24064667
   PubMed Web of Science ®Google Scholar
• Abd Al Samid M, Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients. Oncotarget. 2016;7:14083–94. doi:10.18632/oncotarget.7334. PMID:26885615
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Schilling B, Harasymczuk M, Hoffmann TK, Johnson J, Lang S, Whiteside TL. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol. 2012;42:1876–85. doi:10.1002/eji.201142347. PMID:22585562
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother. 2014;63:67–72. doi:10.1007/s00262-013-1490-y. PMID:24213679
   PubMed Web of Science ®Google Scholar
• Collin M. Immune checkpoint inhibitors: a patent review (2010-2015). Expert Opin Ther Pat. 2016;26:555–64. doi:10.1080/13543776.2016.1176150. PMID:27054314
   PubMed Web of Science ®Google Scholar
• Mahmud SA, Manlove LS, Schmitz HM, Xing Y, Wang Y, Owen DL, Schenkel JM, Boomer JS, Green JM, Yagita H, et al. Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. Nat Immunol. 2014;15:473–81. doi:10.1038/ni.2849. PMID:24633226
   PubMed Web of Science ®Google Scholar
• Govindaraj C, Scalzo-Inguanti K, Madondo M, Hallo J, Flanagan K, Quinn M, Plebanski M. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol. 2013;149:97–110. doi:10.1016/j.clim.2013.07.003. PMID:23948613
   PubMed Web of Science ®Google Scholar
• Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF. CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression. Oncoimmunology. 2015;4:e1003015. doi:10.1080/2162402X.2014.1003015. PMID:26155397
   PubMed Web of Science ®Google Scholar
• Al-Lamki RS, Sadler TJ, Wang J, Reid MJ, Warren AY, Movassagh M, Lu W, Mills IG, Neal DE, Burge J, et al. Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol. 2010;177:943–54. doi:10.2353/ajpath.2010.091218. PMID:20566746
   PubMed Web of Science ®Google Scholar
• Plitas G, Rudensky AY. Regulatory T Cells: Differentiation and Function. Cancer Immunol Res. 2016;4:721–5. doi:10.1158/2326-6066.CIR-16-0193. PMID:27590281
   PubMed Web of Science ®Google Scholar
• Robins HS, Ericson NG, Guenthoer J, O'Briant KC, Tewari M, Drescher CW, Bielas JH. Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med. 2013;5:214ra169. doi:10.1126/scitranslmed.3007247. PMID:24307693
   PubMed Web of Science ®Google Scholar
• Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80. doi:10.1186/gb-2004-5-10-r80. PMID:15461798
   PubMed Web of Science ®Google Scholar